Back to Search
Start Over
Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2012 Sep; Vol. 53 (9), pp. 1817-9. Date of Electronic Publication: 2012 Mar 01. - Publication Year :
- 2012
- Subjects :
- Adult
Aged
Alemtuzumab
Antibodies, Monoclonal, Humanized administration & dosage
Antineoplastic Agents administration & dosage
Antineoplastic Agents therapeutic use
Chromosome Deletion
Chromosomes, Human, Pair 17 genetics
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Antibodies, Monoclonal, Humanized therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Mutation
Tumor Suppressor Protein p53 genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 53
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Editorial & Opinion
- Accession number :
- 22263566
- Full Text :
- https://doi.org/10.3109/10428194.2012.658794